Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL

di Kater, Arnon P., Kersting, Sabina, van Norden, Yvette, Dubois, Julie, Dobber, Johan A., Mellink, Clemens H., Evers, Ludo M., Croon-de Boer, Fransien, Schreurs, John, van der Spek, Ellen, Visser, Hein, Idink, Cecile, Wittebol, Shulamiet, Hoogendoorn, Mels, Tonino, Sanne H., Mobasher, Mehrdad, Levin, Mark-David
Pubblicato in Blood Adv (2018)

Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study

di Sharman, Jeff P., Forero-Torres, Andres, Costa, Luciano J., Flinn, Ian W., Inhorn, Lowell, Kelly, Kevin, Bessudo, Alberto, Fayad, Luis E., Kaminski, Mark S., Evens, Andrew M., Flowers, Christopher R., Sahin, Deniz, Mundt, Kirsten E., Sandmann, Thomas, Fingerle-Rowson, Günter, Vignal, Charlotte, Mobasher, Mehrdad, Zelenetz, Andrew D.
Pubblicato in Leuk Lymphoma (2018)

Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma

di Zinzani, Pier Luigi, Flinn, Ian W., Yuen, Sam L. S., Topp, Max S., Rusconi, Chiara, Fleury, Isabelle, Le Dû, Katell, Arthur, Christopher, Pro, Barbara, Gritti, Giuseppe, Crump, Michael, Petrich, Adam, Samineni, Divya, Sinha, Arijit, Punnoose, Elizabeth A., Szafer-Glusman, Edith, Spielewoy, Nathalie, Mobasher, Mehrdad, Humphrey, Kathryn, Kornacker, Martin, Hiddemann, Wolfgang
Pubblicato in Blood (2020)

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

di Flinn, Ian W., Gribben, John G., Dyer, Martin J. S., Wierda, William, Maris, Michael B., Furman, Richard R., Hillmen, Peter, Rogers, Kerry A., Iyer, Swaminathan Padmanabhan, Quillet-Mary, Anne, Ysebaert, Loic, Walter, Harriet S., Verdugo, Maria, Klein, Christian, Huang, Huang, Jiang, Yanwen, Lozanski, Gerard, Pignataro, Daniela Soriano, Humphrey, Kathryn, Mobasher, Mehrdad, Kipps, Thomas J.
Pubblicato in Blood (2019)

Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

di de Weerdt, Iris, Hofland, Tom, de Boer, Renate, Dobber, Johan A., Dubois, Julie, van Nieuwenhuize, Denise, Mobasher, Mehrdad, de Boer, Fransien, Hoogendoorn, Mels, Velders, Gerjo A., van der Klift, Marjolein, Remmerswaal, Ester B. M., Bemelman, Frederike J., Niemann, Carsten U., Kersting, Sabina, Levin, Mark-David, Eldering, Eric, Tonino, Sanne H., Kater, Arnon P.
Pubblicato in Blood Adv (2019)

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial

di Zelenetz, Andrew D., Salles, Gilles, Mason, Kylie D., Casulo, Carla, Le Gouill, Steven, Sehn, Laurie H., Tilly, Herve, Cartron, Guillaume, Chamuleau, Martine E. D., Goy, Andre, Tam, Constantine S., Lugtenburg, Pieternella J., Petrich, Adam M., Sinha, Arijit, Samineni, Divya, Herter, Sylvia, Ingalla, Ellen, Szafer-Glusman, Edith, Klein, Christian, Sampath, Deepak, Kornacker, Martin, Mobasher, Mehrdad, Morschhauser, Franck
Pubblicato in Blood (2019)

Venetoclax and obinutuzumab in chronic lymphocytic leukemia

di Fischer, Kirsten, Al-Sawaf, Othman, Fink, Anna-Maria, Dixon, Mark, Bahlo, Jasmin, Warburton, Simon, Kipps, Thomas J., Weinkove, Robert, Robinson, Sue, Seiler, Till, Opat, Stephen, Owen, Carolyn, López, Javier, Humphrey, Kathryn, Humerickhouse, Rod, Tausch, Eugen, Frenzel, Lukas, Eichhorst, Barbara, Wendtner, Clemens-M., Stilgenbauer, Stephan, Langerak, Anton W., van Dongen, Jacque J. M., Böttcher, Sebastian, Ritgen, Matthias, Goede, Valentin, Mobasher, Mehrdad, Hallek, Michael
Pubblicato in Blood (2017)

Risk Model for Overall Survival in Relapsed or Refractory Chronic Lymphocytic Leukaemia in the Era of Targeted Therapies

di Soumerai, Jacob D., Ni, Ai, Darif, Mohamed, Londhe, Anil, Xing, Guan, Mun, Yong, Kay, Neil E., Shanafelt, Tait D., Rabe, Kari G., Byrd, John C., Chanan-Khan, Asher A., Furman, Richard R., Hillmen, Peter, Jones, Jeffrey, Seymour, John F., Sharman, Jeffrey P., Ferrante, Lucille, Mobasher, Mehrdad, Stark, Thomas, Reddy, Vijay, Dreiling, Lyndah K., Bhargava, Pankaj, Howes, Angela, James, Danelle F., Zelenetz, Andrew D.
Pubblicato in Lancet Haematol (2019)